Servier expands Tibsovo label with first combination OK in a rare form of AML
Just over a year after Servier shelled out nearly $2 billion to pick up Agios’ oncology portfolio — including the acute myeloid leukemia drug Tibsovo — the French pharma has scored an approval in combination with a commonly used chemotherapy.
Servier secured an approval on Thursday for Tibsovo to treat certain newly diagnosed IDH1-mutated AML patients alongside azacitidine, which is sold by Bristol Myers Squibb under the brand name Vidaza.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.